Emil Lou, Professor with Tenure at University of Minnesota, shared a post on LinkedIn:
“The microbiome has been cited a lot in recent years in relation to efficacy of immunotherapy, and even in causing the rise in young-adult cancers, particularly colorectal cancer. What’s the science behind it, and implications of modulating the gut microbiome to increase the chances immunotherapies will work better?
Check out this new publication in The Oncologist Journal from our University of Minnesota Medical School multidisciplinary team, led by translational GI oncology colleague Dr. Ajay Prakash.”
Other articles featuring Emil Lou on OncoDaily.